PaxVax has two FDA-approved vaccines that could deliver about $70 million to $90 million to Emergent’s top line in 2019.

Here is some other vaccine news of note for the week.

Initial lab work suggests that the Ebola Zaire strain—the one targeted by Merck's rVSV-ZEBOV—is likely the cause of this outbreak.

The sale gives Dendreon better access to capital for expansion and deals, its top executive said—perhaps into CAR-T or other cell therapies, an area where the…

Here is some other vaccine news of note for the week.

Merck's HPV shot, Gardasil, continued to gain steam in the second quarter, and execs see "significant" growth prospects ahead.

Sanofi will increase the supplies of Flublok Quadrivalent and Fluzone High-Dose to 25 million doses for the coming flu season.

Changchun Changsheng “systematically fabricated production and testing records,” a Chinese central government investigation team reported.